Palisade Bio Begins Dosing Ulcerative Colitis Patients in PALI-2108 Trial

MT Newswires Live
03-14

Palisade Bio (PALI) said Friday it began dosing ulcerative colitis patients in the final cohort of its phase 1a/b study of PALI-2108.

The company said it had completed five single ascending dose cohorts and three of four multiple ascending dose cohorts, with no serious adverse events or treatment-related adverse events tied to lab results or EKGs.

Palisade Bio said it plans to report topline data in H1.

Shares of the company were up 3% in recent Friday premarket activity.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10